|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis显示文摘AIM To evaluate the safety and efficacy of tenofovir disoproxil fumarate(TDF) as a first-line therapy in decompensated liver disease. METHODS We enrolled 174 chronic hepatitis B-related liver cirrhosis patients treated with 300 mg/d TDF at six Korean centers. Of the 174 cirrhosis patients, 57 were assigned to the decompensated cirrhosis group and 117 were assigned to the compensated cirrhosis group. We followed the patients for 12 mo and evaluated clinical outcomes, including biochemical, virological, and serological responses. We also evaluated changes in hepatic and renal function and compared the decompensated and compensated cirrhosis groups. RESULTS The 1-year complete virological response(CVR) and Hepatitis B e antigen(HBe Ag) seroconversion were seen in 70.2% and 14.2% in the decompensated cirrhosis group, respectively. The rates of HBe Ag seroconversion/loss and ALT normalization at month 12 were similar in both groups. TDF treatment was also effective for decreasing the level of hepatitis B virus(HBV) DNA in both groups, but CVR was higher in the compensated group(88.9% vs 70.2%, P = 0.005). Tenofovir treatment for 12 mo resulted in improved Child-Turcotte-Pugh(CTP) and model for end-stage liver disease(MELD) scores in decompensated group(P < 0.001). Of the 57 decompensated patients, 39(68.4%) achieved CTP class A and 27(49.1%) showed improvement in the CTP score of 2 points after 12 mo of TDF. The observed rate of confirmed 0.5 mg/d L increases in serum levels of creatinine in the decompensated and compensated cirrhosis group were 7.0% and 2.5%, respectively(P < 1.000).CONCLUSION TDF therapy in decompensated cirrhosis patients was effective for decreasing HBV DNA levels and improving hepatic function with relatively lower CVR than in compensated cirrhosis. Thus, physicians should carefully monitor not only renal function but also treatment responses when using TDF in decompensated cirrhosis patients. | Soon Kyu Lee Myeong Jun Song Seok Hyun Kim Byung Seok Lee Tae Hee Lee Young Woo Kang Suk Bae Kim Il Han Song Hee Bok Chae Soon Young Ko Jae Dong Lee | 2017 | World Journal of Gastroenterology2017，23，13： | 14 |
| 2 | Collision tumor of hepatocellular carcinoma and neuroendocrine carcinoma involving the liver: Case report and review of the literature显示文摘Primary hepatic neuroendocrine carcinoma(NEC) with concurrent occurrence of hepatocellular carcinoma(HCC) of the liver is very rare. Only 8 cases have been reported in the literature. Concurrent occurrence of HCC and NEC in the liver is classified as combined type or collision type by histological distributional patterns; only 2 cases have been reported. Herein, we report a case of collision type concurrent occurrence of HCC and NEC, in which primary hepatic NEC was in only a small portion of the nodule, which is different from the 2 previously reported cases. A 72-year-old male with chronic hepatitis C was admitted to our hospital for a hepatic mass detected by liver computed tomography(CT) at another clinic. Because the nodule was in hepatic segment 3 and had proper radiologic findings for diagnosis of HCC, including enhancement in the arterial phase and wash-out in the portal and delay phases, the patient was treated with laparoscopic left lateral sectionectomy. The pathology demonstrated that the nodule was 2.5 cm and was moderately differentiated HCC. However, a 3 mm-sized focal neuroendocrine carcinoma was also detected on the capsule of the nodule. The tumor was concluded to be a collision type with HCC and primary hepatic NEC. After the surgery, for follow-up, the patient underwent a liver CT every 3 mo. Five multiple nodules were found in the right hepatic lobe on the follow-up liver CT 6 mo post-operatively. As the features of the nodules in the liver CT and MRI were different from that of HCC, a liver biopsy was performed. Intrahepatic recurrent NEC was proven after the liver biopsy, which showed the same pathologic features with the specimen obtained 6 mo ago. Palliative chemotherapy with a combination of etoposide and cisplatin has been administered for 4 months, showing partial response. | Gyu Ho Choi Sun Young Ann Soon Il Lee Suk BaeKim Il Han Song | 2016 | World Journal of Gastroenterology2016，22，41： | 8 |
| 3 | Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy显示文摘Hepatocellular carcinoma(HCC)is a grave primary liver cancer that has a limited therapeutic option because it is generally diagnosed later in an advanced stage due to its aggressive biologic behavior.The early detection of HCC has a great impact on the treatment efficacy and survival of patients at high risk for cancer.Potential host,environmental,and virus-related risk factors have been introduced.Hepatitis B virus(HBV)is a major cause of end-stage liver diseases such as liver cirrhosis or HCC in endemic areas,and its serologic or virologic status is considered an important risk factor.HCC risk prediction derived from the identification of major risk factors is necessary for providing adequate screening/surveillance strategies to high-risk individuals.Several risk prediction models for HBV-related HCC have been presented recently with simple,efficient,and readily available to use parameters applicable to average-or unknown-risk populations as well as high-risk individuals.Predictive scoring systems of risk estimation to assess HCC development can provide the way to an evidence-based clinical approach for cost-and effort-effective outcomes,capable of inducing a personalized surveillance program according to risk stratification.In this review,the concepts and perspectives of the risk prediction of HCC are discussed through the analysis of several risk prediction models of HBV-related HCC. | Il Han Song So Mi Kim Young Kwang Choo | 2013 | World Journal of Gastroenterology2013，19，47： | 7 |
| 4 | Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-na?ve chronic hepatitis B: A case report and review of the literature显示文摘Tenofovir disoproxil fumarate(TDF) is a potent nucleo-tide analogue that is recommended as first-line therapy for patients with chronic hepatitis B. The results of a longitudinal study of TDF treatment demonstrated no development of resistance. We observed one treatment-na?ve chronic hepatitis B(CHB) patient who developed TDF resistance after complete viral suppression during long-term TDF treatment. A 37-year-old HBe Ag-positive man received TDF 300 mg/d for 43 mo. The hepatitis B virus(HBV) DNA titer was 8 log_(10) copies/m L at baseline and became undetectable at 16 mo after treatment. However, the HBV DNA titer rebounded to 7.5 log_(10) copies/m L at 43 mo after treatment. We performed full sequencing to find mutation sites associated with virologic breakthrough. The results showed 9 mutation sites, most of which had not been well-known as mutation sites. We changed the therapy from tenofovir to entecavir with a regimen of 0.5 mg once daily. After 4 mo, the HBV DNA titer decreased to 267 copies/m L, and the liver enzyme levels were normalized. | Woo Hee Cho Hyun Jae Lee Ki Bae Bang Seok Bae Kim Il Han Song | 2018 | World Journal of Gastroenterology2018，24，17： | 5 |
| 5 | Clinical Outcomes of Patients with Liver Cirrhosis Who Underwent Curative Surgery for Gastric Cancer: A Retrospective Multi-center Study显示文摘 | Hyun Joo Jang Jung Han Kim Hun Ho Song Kyung Hee Woo Mi Kim Sea Hyub Kae Jin Lee Ji Wong Cho Jung Hun Kang Soon Il Lee Soo Jung Gong Jung Ae Lee Dae Young Zang | 2008 | Digestive Diseases and Sciences2008，，2： | 1 |
| 6 | Morbidity and mortality after non‐curative gastrectomy for gastric cancer in elderly patients显示文摘 | Jung Ho Shim Kyung Jai Ko Han Mo Yoo Seong Il Oh Dong Jin Jeon Hae Myung Jeon Cho Hyun Park Kyo Young Song | 2012 | J Surg Oncol2012，，6： | 1 |
| 7 | Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level显示文摘 | Jai Hyuen Lee Seok Gun Park Keum Nahn Jee Dong Guk Park Hwan Namgung Il Han Song | 2010 | Nuclear Medicine Communications2010，，6： | 1 |
| 8 | Various types of intracorporeal esophagojejunostomy after laparoscopic total gastrectomy for gastric cancer显示文摘 | Jung Ho Shim Han Mo Yoo Seong Il Oh Myung Jin Nam Hae Myung Jeon Cho Hyun Park Kyo Young Song | 2013 | Gastric Cancer2013，，3： | 1 |
| 9 | Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01)显示文摘 | Wook Kim Hyung-Ho Kim Sang-Uk Han Min-Chan Kim Woo Jin Hyung Seung Wan Ryu Gyu Seok Cho Chan Young Kim Han-Kwang Yang Do Joong Park Kyo Young Song Sang Il Lee Seung Yub Ryu Joo-Ho Lee Hyuk-Joon Lee | 2016 | Annals of Surgery2016，，1： | 1 |
| 10 | Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B显示文摘AIM:To evaluate the treatment outcomes of clevudine compared with entecavir in antiviral-naive patients with chronic hepatitis B(CHB).METHODS:We retrospectively analyzed the clinical data of CHB patients treated with clevudine 30 mg/d and compared their clinical outcomes with patients treated with entecavir 0.5 mg/d.The biochemical response,as assessed by serum alanine aminotransferase(ALT) activity,virologic response,as assessed by serum hepatitis B virus DNA(HBV DNA) titer,serologic response,as assessed by hepatitis B e antigen(HBeAg) status,and virologic breakthrough with genotypic mutations were assessed.RESULTS:Two-hundred and fifty-four patients [clevudine(n = 118) vs entecavir(n = 136)] were enrolled.In clevudine-treated patients,the cumulative rates of serum ALT normalization were 83.9% at week 48 and 91.5% at week 96(80.9% and 91.2% in the entecavir group,respectively),the mean titer changes in serum HBV DNA were-6.03 and-6.55 log 10 copies/mL(-6.35 and-6.86 log 10 copies/mL,respectively,in the entecavir group),and the cumulative non-detection rates of serum HBV DNA were 72.6% and 83.1%(74.4% and 83.8%,respectively,in the entecavir group).These results were similar to those of entecavir-treated patients.The cumulative rates of HBeAg seroconversion were 21.8% at week 48 and 25.0% at week 96 in patients treated with clevudine,which was similar to patients treated with entecavir(22.8% and 27.7%,respectively).The virologic breakthrough in the clevudine group occurred in 9(7.6%) patients at weeks 48 and 15(12.7%) patients at week 96,which primarily corresponded to genotypic mutations of rtM204I and/or rtL180M.There was no virologic breakthrough in the entecavir group.CONCLUSION:In antiviral-naive CHB patients,longterm treatment outcomes of clevudine were not inferior to those of entecavir,except for virologic breakthrough. | Suk Bae Kim Il Han Song Young Min Kim Ran Noh Ha Yan Kang Hyang Ie Lee Hyeon Yoong Yang An Na Kim Hee Bok Chae Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Eaum Seok Lee Seok Hyun Kim Byung Seok Lee Heon Young Lee | 2012 | World Journal of Gastroenterology2012，18，47： | 1 |
| 11 | Multicenter Analysis of Clinicopathologic Features of Intraductal Papillary Mucinous Tumor of the Pancreas: Is It Possible to Predict the Malignancy Before Surgery?显示文摘 | Jin-Young Jang MD Sun-Whe Kim MD FACS Young Joon Ahn MD Yoo-Seok Yoon MD Min Gew Choi MD Kuhn Uk Lee MD Joon Koo Han MD Woo Ho Kim MD Young Joo Lee MD Song Chul Kim MD Duck Jong Han MD Yong Il Kim MD Seong Ho Choi MD Baik Hwan Cho MD Hee Chul Yu MD Dong | 2005 | Annals of Surgical Oncology2005，，2： | 1 |
| 12 | 基于Verhulst灰色模型的矿山巷道流变性围岩地质工学参数智能反分析显示文摘采用基于灰色Verhulst模型(GVM)的智能反分析(IBA)方法确定隧道围岩的岩土参数,并通过对朝鲜“6.13”煤矿−600 m水平主巷道试验验证了该方法的准确性。用于反分析的位移分量为开挖结束时监测到的拱顶沉降和边墙收敛量,以及GVM预测的最终闭合量。利用FLAC3D的人工神经网络(ANN)和Burgers蠕变粘塑性(CVISC)模型,得到了位移与反分析参数之间的非线性关系。然后,利用遗传算法(GA)确定了隧道围岩的最优参数,并利用GVM预测了最终开挖和闭坑时的两组实测位移。采用反分析参数数值模拟的计算位移与原位位移的最大绝对误差(MAE)和标准差(Std)分别小于6 mm和2 mm。结果表明,该方法可用于确定巷道、地下空区、矿山空场和采场的设计参数和稳定性。 | Un Chol HAN Chung Song CHOE Kun Ui HONG Hyon Il HAN | 2021 | Journal of Central South University2021，28，10： | 1 |
| 13 | Lung Function Changes in Sprague-Dawley Rats After Prolonged Inhalation Exposure to Silver Nanoparticles显示文摘 | Jae Hyuck Sung Jun Ho Ji Jin Uk Yoon Dae Seong Kim Moon Yong Song Jayoung Jeong Beom Seok Han Jeong Hee Han Yong Hyun Chung Jeongyong Kim Tae Sung Kim Hee Kyung Chang Eun Jung Lee Ji Hyun Lee Il Je Yu | 2008 | Inhalation Toxicology2008，，6： | 1 |
| 14 | Autoimmune hepatitis in a patient with immunoglobulin A nephropathy:A case report显示文摘BACKGROUND Immunoglobulin A nephropathy(IgAN)is the most commonly encountered glomerular disease in Asian countries.It has a broad clinical presentation,and it is frequently associated with other conditions.Chronic liver disease is well recognized as the leading cause of secondary IgAN.However,cases of IgAN associated with autoimmune hepatitis(AIH)have seldom been reported.CASE SUMMARY A 63-year-old Korean woman was admitted to Pusan National University Hospital for an evaluation of abdominal pain and elevated liver enzymes.Two weeks prior,she had presented to our hospital with proteinuria of approximately 1350 mg/d and hematuria and was diagnosed with IgAN.Autoimmune profiles were highly positive for antinuclear antibodies,and symptoms related to portal hypertension including ascites and peripheral edema were present.A diagnosis of AIH was made according to the simplified scoring system of the International Autoimmune Hepatitis Group.Despite immunosuppression with prednisolone and azathioprine,rapid deterioration of liver function led to end-stage liver disease.After a living-donor liver transplantation,liver function gradually improved,and she had maintained stable liver and kidney function at the six months follow-up.CONCLUSION Cases of secondary IgAN with chronic liver disease have been frequently reported in the literature but are rarely associated with AIH.We encountered an IgAN patient with concurrent progressive liver failure due to AIH. | You Hyun Jeon Da Woon Kim So Jeong Lee Young Joo Park Hyo Jin Kim Miyeun Han Il Young Kim Dong Won Lee Sang Heon Song Soo Bong Lee Eun Young Seong | 2020 | World Journal of Clinical Cases2020，8，17： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员